OR WAIT null SECS
The new service offers a flexible, customizable suite of products and services designed to accelerate the clinical and commercial development of gene and cell therapies.
Precision NanoSystems (PNI), a biotechnology company specializing in solutions for the development of genetic nanomedicines used in oncology, rare disease, and infectious disease, announced on April 9, 2019 that it launched its clinical solutions service to accelerate the clinical and commercial development of gene and cell therapies.
PNI is offering this new service as a response to repeated requests from clients progressing their programs towards the clinic for support across all aspects of nanomedicine clinical development. According to the company, its clinical solutions offers a flexible, customizable suite of products and services that maximize the effectiveness of clinical and commercial nanomedicine development by leveraging client capabilities and resources with the company’s NanoAssemblr technology, nanomedicine development services, and value-added partners.
The services are suitable for virtual companies and multinational pharmaceutical organizations developing nanomedicines. The NanoAssemblr technology platform enables rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body.
“We are dedicated to enabling the success of our client’s nanomedicine development programs”, said Euan Ramsay, chief commercial officer of Precision NanoSystems, in a company press release. “Clinical [s]olutions is designed to provide a one-stop-shop for all nanomedicine clinical development needs, such as sourcing GMP excipients, developing analytical methods, building [q]uality [m]anagement [s]ystems or accessing experienced [c]ontract [m]anufacturing [o]rganizations.”
Source: Precision NanoSystems